ABVC BioPharma, Inc. (ABVC) has issued an update.
ABVC BioPharma has announced corrections to a previous press release concerning their licensing deals with AiBtl, ForSeeCon, and OncoX. The company clarified that the potential aggregate license fee is $19 million, not $24 million as initially reported. Furthermore, the expected total cash payment from these licensees is $18.7 million, contrary to the previously stated $23.7 million.
For an in-depth examination of ABVC stock, go to TipRanks’ Stock Analysis page.
